WEKO3
アイテム
IMPROVEMENTS IN HELICOBACTER PYLORI ERADICATION RATES THROUGH CLINICAL CYP2C19 GENOTYPING
https://doi.org/10.18999/nagjms.73.1-2.25
https://doi.org/10.18999/nagjms.73.1-2.254a8e1f59-95f9-409b-8502-4204ddd9cffc
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
v73n12p25_31.pdf (94.3 kB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2011-06-01 | |||||
| タイトル | ||||||
| タイトル | IMPROVEMENTS IN HELICOBACTER PYLORI ERADICATION RATES THROUGH CLINICAL CYP2C19 GENOTYPING | |||||
| 言語 | en | |||||
| 著者 |
TAMURA, TAKASHI
× TAMURA, TAKASHI× KURATA, MIO× INOUE, SHIGERU× KONDO, TAKAAKI× GOTO, YASUYUKI× KAMIYA, YOSHIKAZU× KAWAI, SAYO× HAMAJIMA, NOBUYUKI |
|||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Helicobacter pylori | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | CYP2C19 genotype | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Proton pump inhibitor | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Eradication rate | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Lansoprazole (LPZ), amoxicillin (AMPC) and clarithromycin (CAM) are commonly used drugs (LAC regimen) for Helicobacter pylori (H. pylori) eradication, but the eradication rate with this regimen was reported to be 70% to 90%. A few studies have reported that a successful eradication was associated with the CYP2C19 genotype, which influences the metabolism of proton pump inhibitors (PPI) including LPZ. This study examined the changes in the H. pylori eradication rates between the periods before and after the commencement of a routine genetic test for CYP2C19 at the Daiko Medical Center in Nagoya, Japan, in November, 2005. Subjects were patients who visited the Center during the period from June, 2004 to August, 2010. The patients were classified into three groups according to their CYP2C19 genotype: rapid metabolizers (RM) with a *1*1 genotype, intermediate metabolizers (IM) with a *1*2 or *1*3 genotype, and poor metabolizers (PM) with a *2*2, *2*3, or *3*3 genotype. Non-rapid metabolizers (IM and PM) were basically treated with a LAC regimen, while RMs were treated with a RAM regimen (rabeprazole, AMPC, and metronidazole). The eradication rate was 80.0% (n=90) for the period without the genetic testing and 88.7% (n=124) for the period with the genetic testing (χ2=3.11, p=0.078). The age-sex adjusted odds ratio of eradication success was 2.29 (95% confidence interval, 0.99–5.28, p=0.051) for the latter period relative to the former period among those less than 70 years of age. Those results suggested that the routine genetic test which allows a choice of the RAM regimen for RM improved the eradication rate. | |||||
| 言語 | en | |||||
| 出版者 | ||||||
| 出版者 | Nagoya University School of Medicine | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| ID登録 | ||||||
| ID登録 | 10.18999/nagjms.73.1-2.25 | |||||
| ID登録タイプ | JaLC | |||||
| 関連情報 | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | URI | |||||
| 関連識別子 | http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7312/7312.html | |||||
| ISSN（print） | ||||||
| 収録物識別子タイプ | PISSN | |||||
| 収録物識別子 | 0027-7622 | |||||
| ISSN（Online） | ||||||
| 収録物識別子タイプ | EISSN | |||||
| 収録物識別子 | 2186-3326 | |||||
| 書誌情報 |
en : Nagoya Journal of Medical Science 巻 73, 号 1-2, p. 25-31, 発行日 2011-02 |
|||||
| 著者版フラグ | ||||||
| 値 | publisher | |||||
| URI | ||||||
| 識別子 | http://hdl.handle.net/2237/14912 | |||||
| 識別子タイプ | HDL | |||||
